BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26025260)

  • 1. 2015 American Thoracic Society International Conference.
    Akkermans R
    Lancet Respir Med; 2015 Jul; 3(7):513-5. PubMed ID: 26025260
    [No Abstract]   [Full Text] [Related]  

  • 2. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 3. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 4. Radical new treatments for cystic fibrosis.
    Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
    [No Abstract]   [Full Text] [Related]  

  • 5. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 7. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA moves on breakthrough therapies.
    Fox JL
    Nat Biotechnol; 2013 May; 31(5):374. PubMed ID: 23657379
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
    Nau JY
    Rev Med Suisse; 2015 May; 11(476):1210-1. PubMed ID: 26182641
    [No Abstract]   [Full Text] [Related]  

  • 10. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 11. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2016 American Thoracic Society International Conference.
    Akkermans R
    Lancet Respir Med; 2016 Jul; 4(7):538-539. PubMed ID: 27237062
    [No Abstract]   [Full Text] [Related]  

  • 13. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 14. New Drugs 2019, part 1.
    Hussar DA
    Nursing; 2019 Feb; 49(2):28-36. PubMed ID: 30676555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 16. Vertex CF data wow Wall Street.
    Nat Biotechnol; 2017 Sep; 35(9):807. PubMed ID: 28898228
    [No Abstract]   [Full Text] [Related]  

  • 17. Remarkable progress toward new treatments for cystic fibrosis.
    Eldredge LC; Ramsey BW
    Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
    [No Abstract]   [Full Text] [Related]  

  • 18. Game Changers.
    Ulster Med J; 2015 Oct; 84(3):218-9. PubMed ID: 26668427
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on new pulmonary therapies.
    Retsch-Bogart GZ
    Curr Opin Pulm Med; 2009 Nov; 15(6):604-10. PubMed ID: 19696677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis drug Vertex's latest triumph.
    Ledford H
    Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.